NCT00594581View on ClinicalTrials.gov

Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

March 31, 2005

Conditions
Cicatrix
Interventions
DRUG

Juvista (avotermin) plus placebo, standard-care (within-subject controls)

Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin

Trial Locations (1)

M13 9XX

Clinical Trials Unit, Renovo Ltd, Manchester

All Listed Sponsors
lead

Renovo

INDUSTRY

NCT00594581 - Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males | Biotech Hunter | Biotech Hunter